E-viri
PDF
Recenzirano
Odprti dostop
-
Kopetz, Scott; Grothey, Axel; Yaeger, Rona; Van Cutsem, Eric; Desai, Jayesh; Yoshino, Takayuki; Wasan, Harpreet; Ciardiello, Fortunato; Loupakis, Fotios; Hong, Yong Sang; Steeghs, Neeltje; Guren, Tormod K; Arkenau, Hendrik-Tobias; Garcia-Alfonso, Pilar; Pfeiffer, Per; Orlov, Sergey; Lonardi, Sara; Elez, Elena; Kim, Tae-Won; Schellens, Jan H.M; Guo, Christina; Krishnan, Asha; Dekervel, Jeroen; Morris, Van; Calvo Ferrandiz, Aitana; Tarpgaard, L.S; Braun, Michael; Gollerkeri, Ashwin; Keir, Christopher; Maharry, Kati; Pickard, Michael; Christy-Bittel, Janna; Anderson, Lisa; Sandor, Victor; Tabernero, Josep
The New England journal of medicine, 10/2019, Letnik: 381, Številka: 17Journal Article
Colorectal cancers with BRAF mutations have an aggressive natural history and are often resistant to therapy. A treatment regimen that combined BRAF inhibition, MET inhibition, and blocking of EGFR signaling resulted in a response rate of 26% and a median overall survival of 9 months.
